




Searching News Database: Cabozantinib
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
HSMN NewsFeed - 16 Jul 2015
Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
Exelixis Appoints Chris Senner as Executive Vice President and Chief Financial Officer
HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib